Project Grant R41CA287794
Award Date 9/16/25
Completion Date 8/31/26
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Colorado, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a Project Grant, CFDA 93.395 "Cancer Treatment Research", to the University of North Carolina at Chapel Hill (UNC-CH) in the amount of $627,456 on December 1, 2024. The purpose of this 5-year grant is to conduct a Phase I clinical trial evaluating the safety and efficacy of a CSPG4-targeted CAR-T cell therapy for the treatment of head and neck squamous cell carcinoma (HNSCC) that is refractory to platinum-based chemotherapy and PD-1...
- The National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), awarded a $400,000 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Nuago Therapeutics Inc. on September 19, 2024. The goal of this STTR project is to develop an RNA interference-based therapeutic to treat prostate cancer. The therapeutic, termed "NU002", will use lipopolyplex nanoparticles to deliver short interfering RNAs (siRNAs) derived from CAG trinucleotide repeat sequences....
- The National Cancer Institute, under the Cancer Treatment Research federal grant program (CFDA 93.395), awarded a $400,000 project grant to Nuago Therapeutics Inc. on June 9, 2025. The grant supports the development of a short RNA therapeutic to treat ovarian cancer. This research aims to develop a novel, targeted cancer therapy that can potentially overcome limitations of existing cancer treatments. The award has a projected completion date of May 31, 2026 and will be conducted at the company's...
- The National Cancer Institute (NCI) awarded a $306,871 Project Grant to Vivere Oncotherapies, Inc. under the Cancer Treatment Research federal grant program (CFDA 93.395) to advance the development of their OV-151 oncolytic virotherapy product for the treatment of colorectal cancer. The project aims to: 1) characterize the delivery properties of the OV-151 clinical vector to tumors, 2) optimize the therapeutic cargo delivered by the vector, and 3) develop an inducible promoter to enhance...
- This $306,265 federal Project Grant, awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) on September 16, 2025, will fund the preclinical development of VAX024 - a novel, second-generation recombinant bacterial minicell-based targeted oncolytic in situ immunization (ISI) agent. VAX024 is designed to overcome limitations of current oncolytic viral therapies by leveraging the grantee's proprietary delivery technology to generate a sterile, user-friendly oncolytic...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) has awarded Emory University a Project Grant of $156,500.00 to conduct a comprehensive multi-omics investigation of the pathophysiology of cachexia in head and neck squamous cell carcinoma (HNSCC) patients. The 2-year project, running from August 1, 2025 to July 31, 2027, aims to gain a deeper understanding of the early biological mechanisms driving cachexia, a lethal syndrome affecting up to 80% of advanced cancer patients....
- This $406,500 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a novel intratumoral delivery system by Absco Therapeutics, Inc. (Abscotx) to enhance solid tumor immunotherapy. The Oncolymer platform utilizes a thermoresponsive hydrogel and FDA-approved imaging agent to enable sustained, localized delivery of therapeutic agents like immune-sensitizing siRNA and the TLR7 agonist imiquimod. Preclinical studies have...
- The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $317,000 project grant (CFDA No. 93.121 - Oral Diseases and Disorders Research) to Temple University to investigate the role of amplified protein kinases in head and neck squamous cell carcinoma (HNSCC) progression and therapy resistance. The 2-year project aims to test whether the protein kinase TNIK, which is amplified in 20% of HNSCC cases, sustains HNSCC cell proliferation and viability by activating focal...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $276,544 Project Grant to Ioncologi Inc. on September 1, 2025. The grant supports the development of IOI7, an autologous, ex vivo-expanded, immunomodulatory hematopoietic stem cell (HSC) therapy, for the treatment of immune checkpoint inhibitor-resistant glioblastoma. The key objectives are to: (1) optimize HSC expansion using a closed, scalable, and commercially viable production platform; (2) validate HSC...
- This federal Project Grant award of $249,000.00, provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), supports research to develop a novel patient-derived tumor organoid (tumoroid) platform for precision treatment of head and neck squamous cell carcinomas (HNSCCS). The key products and services to be delivered include: Establishing a high-throughput automated HNSCC tumoroid platform to capture tumor...